Effect of body mass index on survival after curative therapy for non-B non-C hepatocellular carcinoma

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 2, 2013, Pages 173-181

  Nishikawa, Hiroki ^a   Osaki, Yukio ^a   Takeda, Haruhiko ^a   Sakamoto, Azusa ^a   Saito, Sumio ^a   Nishijima, Norihiro ^a   Nasu, Akihiro ^a   Arimoto, Akira ^a   Kita, Ryuichi ^a   Kimura, Toru ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Curative therapy; Non B non C hepatocellular carcinoma; Obesity; Overall survival; Recurrence free survivall

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DECARBOXYPROTHROMBIN; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; SERUM ALBUMIN;

AGED; ARTICLE; BODY MASS; CANCER RECURRENCE; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMORBIDITY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBESITY; OVERALL SURVIVAL; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879181186     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Livraghi T, Mäkisalo H, Line PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011; 100: 22-29.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
3. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012; 56 Suppl 1: S75-S87.
4. Kaibori M, Ishizaki M, Matsui K, Kwon AH. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy Am J Surg 2012; 204: 300-307.
5. Yotsuyanagi H, Shintani Y, Moriya K, et al. Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus. J Infect Dis 2000; 181: 1920-1928.
6. Utsunomiya T, Shimada M. Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res 2011; 41: 711-721.
7. Ikeda K, Kobayashi M, Someya T, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009; 16: 437-443.
8. Kusakabe A, Tanaka Y, Orito E, et al. A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol 2007; 42: 298-305.
9. Tamori A, Nishiguchi S, Kubo S, et al. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol 2003; 71: 492-498.
10. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007; 37 Suppl 2: S95-S100.
11. Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 2009; 249: 195-202.
12. Nishikawa H, Osaki Y, Kita R, et al. Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol 2012; 41: 903-909.
13. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol 2013;42:151-160.
14. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
15. WHO: World Health Organization. Fact Sheet for World Wide. Prevalence of Obesity. [(accessed on 27 December 2011)]. Available online: http://www.who.int/mediacentre/factsheets/fs311/en/ indexhtml.
16. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1): S97-S103.
17. Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13-21.
18. Møller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30A: 344-350.
19. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-1213.
20. Obesity-preventing and managing the global epidemic. Report of WHO consultation. World Health Organ Tech Rep Ser 2000;894:1-253.
21. McCurry J. Japan battles with obesity. Lancet 2007; 369: 451-452.
22. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J 2002; 66: 987-992.
23. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
24. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
25. The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg 1989; 19: 98-129.
26. Komura T, Mizukoshi E, Kita Y, et al. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 2007;102:1939-1946.
27. Shau WY, Shao YY, Yeh YC, et al. Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist 2012;17:856-862.
28. Akiyama T, Mizuta T, Kawazoe S, et al. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World J Gastroenterol 2011; 17: 914-921.
29. Muto Y Sato S, Watanabe A, et al; Long-Term Survival Study (LOTUS) Group. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006; 35: 204-214.
30. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309: 71-82.
31. Peng Y Rideout D, Rakita S, Lee J, Murr M. Diet-induced obesity associated with steatosis, oxidative stress, and inflammation in liver. Surg Obes Relat Dis 2012; 8: 73-81.
32. Davila JA, Morgan RO, Shaib Y McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-539.
33. Nishikawa H, Osaki Y Iguchi E, et al. The Effect of Long-term Supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol 2013;47:359-366.
34. Kobayashi M, Ikeda K, Kawamura Y, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115: 571-580.
35. Yao D, Jiang D, Huang Z, et al. Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000; 88: 761-769.
36. Zhang JB, Chen Y Zhang B, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol 2011; 23: 787-793.
37. Yu MC, Chan KM, Lee CF, et al. Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence? J Gastrointest Surg 2011; 15: 1440-1449.
38. Ju MJ, Qiu SJ, Fan J, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol 2009; 44: 635-642.